@article{article, title  = {{A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS rucaparib arm.}},

 publisher = {{American Society of Clinical Oncology (ASCO)}},

 url = {{}},

 year = {{2022}},

 month = {{2}},

 author = {{Crabb SJ and Hussain SA and Soulis E and Hinsley S and Dempsey L and Trevethan A and Song YP and Barber J and Frew JA and Gale J and Faust G et al}},

 doi = {{10.1200/jco.2022.40.6_suppl.436}},

 volume = {{40}},

 journal = {{Journal of Clinical Oncology}},

 issue = {{6_suppl}},

 pages = {{436-436}},

 note = {{Accessed on 2024/12/22}}}